Oncology Institute, Inc.

TOIIW

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase3 readout (docetaxel): May 2014.

Medical - Care FacilitiesCEO: Daniel VirnichWebsite ↗

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.

Catalysts

Phase 3Q2 2014docetaxelBreast CancerNCT00331097

Primary: disease free survival (at 5 years)Enrollment:300/300Sites: 8RANDOMIZED, TREATMENT

Phase 2Q2 2022TepotinibAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IVNCT02864992

Primary: Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC) (Time from first treatment up to data cutoff (approximately Month 66))Enrollment:337/337Sites: 176NA, TREATMENT

Phase 2Q3 2022CisplatinCarcinoma, Non-Small-Cell LungNCT03840915

Phase 2Q2 2023TepotinibNon-small Cell Lung CancerNCT03940703

Primary: Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0) (Up to Day 21 of Cycle 1 (each Cycle is of 21 days))Enrollment:140/140Sites: 179NON_RANDOMIZED, TREATMENT

Phase 2Q2 2023Folfiri/CetuximabColorectal Cancer, ADCCNCT03874026

Primary: Activity (1 year)Enrollment:Target 34Sites: 1NA, TREATMENT

Phase 2Q1 2025Cabozantinib and TemozolomideLung Neuroendocrine Neoplasm, GEP Neuroendocrine TumorNCT04893785

Primary: To assess the efficacy of the combination of cabozantinib and one-week-on/one-week-off temozolomide, based on overall response rate (ORR). (Up to 42 months)Enrollment:Target 35Sites: 1NA, TREATMENT

Phase 2Q2 2025AvelumabLocally Advanced or Metastatic Urothelial CarcinomaNCT05327530

Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator (Time from randomization of study drug until first documentation of progressive disease (PD) or death, assessed approximately up to 51 months)Enrollment:256/256Sites: 97RANDOMIZED, TREATMENT

Phase 2Q2 2025K-808 (Dose A)Primary Biliary CholangitisNCT06247735

Primary: Percent change from baseline in serum alkaline phosphatase (ALP) (Baseline to Week 12)Enrollment:46/46Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2025Methotrexate InjectionProliferative Vitreoretinopathy, Rhegmatogenous Retinal DetachmentNCT06541574

Primary: Primary Outcome Measure (Month 12)Enrollment:Target 860Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2025Tuvusertib (M1774)Ovarian CancerNCT06433219

Primary: Part A and Part B: Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by Investigator (Time from randomization to final assessment or until progressive disease, death, discontinuation criteria, approximately up to 3.5 years)Enrollment:63/63Sites: 84RANDOMIZED, TREATMENT

Phase 2Q3 2025Durvalumab 1120 mgCholangiocarcinomaNCT06341764

Phase 2Q1 2026M1774Non-Small Cell Lung CancerNCT05882734

Phase 2Q2 2026K-877-ERNASHNCT05327127

Phase 3Q2 2026XR-BOpioid-use DisorderNCT04408313

Primary: pharmacotherapy adherence (6-months post-release)Enrollment:Target 240Sites: 1RANDOMIZED, TREATMENT

Phase 3Q3 2026Extended Release BuprenorphineOpioid Use DisorderNCT07524738

Primary: medication adherence (three months post-release)Enrollment:Target 30Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2026AvelumabSolid TumorsNCT03815643

Primary: Occurrence of Treatment-related Non-serious Treatment-Emergent Adverse Events (TEAEs), All Serious AEs, Immunerelated AEs and Infusion-related Reactions According to Version of National Cancer Institute Common Technology Criteria for Adverse Events (From enrollment to end of survival follow-up (up to 5 years after the last participant receives the last dose of avelumab))Enrollment:205/205Sites: 104NA, TREATMENT

Phase 2Q3 2026Valproic acidAdenocarcinoma of the PancreasNCT05821556

Phase 2Q3 2026Cyclophosphamide and Etoposide in combinationSquamous Cell Carcinoma, Advanced Head and Neck CancerNCT07361133

Phase 2Q4 2026standard second line treatment, at discretion of the investigatorColorectal Cancer MetastaticNCT07213570

Primary: Progression Free Survival rate at 6 months in the two arms. (up to 6 months from randomization)Enrollment:Target 60Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2026irinotecanColorectal Cancer MetastaticNCT06714357

Primary: Study Part 1 - Progression Free Survival rate at 16 weeks in the two arms. (up to 16 weeks from randomization)Enrollment:Target 130Sites: 8RANDOMIZED, TREATMENT

Phase 2Q1 2027Prophylactic Plasma TransfusionLeptospirosisNCT07127718

Phase 2Q2 2027Prostate Cancer (Adenocarcinoma)NCT07302451

Primary: Recovery of Erectile Function (IIEF-5) at 6 Months Post-ADT: ≥70% Threshold for Study Success (6 months after completion of hormonal therapy (Relugolix))Enrollment:Target 50Sites: 1NA, TREATMENT

Phase 3Q2 2027Methadone Treatment-As-UsualOpioid Use, Opioid Use Disorder, Cocaine UseNCT05766631

Phase 2Q3 2027dornase alfa i.v. and cisplatinRefractory Germ Cell Tumors, Dornase AlfaNCT07121322

Phase 2Q3 2027standard nivolumab and oxaliplatin- based chemotherapyAdvanced or Metastatic Gastrooesophageal CarcinomaNCT07213557

Primary: Progression Free Survival rate at 1-year (PFS 1-year) (up to 1 year to randomization)Enrollment:Target 84Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2027M9140Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC)NCT06710132

Phase 2Q1 2028Cannabis Extract OilAdvanced Malignant Solid TumorNCT07459920

Phase 3Q1 2028OlaparibOvarian CancerNCT05255471

Phase 3Q1 2028PanitumumabColorectal Cancer Stage IVNCT06509126

Phase 3Q2 202811-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)HPV Infectio N, HPV-Related CarcinomaNCT05262010

Phase 3Q3 2028extended-release buprenorphine (XR-B)Opioid Use DisorderNCT06306443

Phase 3Q4 2028Precemtabart tocentecanMetastatic Colorectal CancerNCT07549412

Phase 3Q2 2029EnpatoranSystemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)NCT07332481

Phase 3Q2 2029EnpatoranSystematic Lupus Erythematosus, Cutaneous Lupus ErythematosusNCT07355218

Phase 2Q2 2030InavolisibEndometrial CancerNCT07522697

Primary: Objective response rate (ORR) (Every 8 (±1) weeks during the first 2 years, every 12 (±1) weeks therafter, from enrollment until disease progression (up to 48 months).)Enrollment:Target 48Sites: 1NA, TREATMENT

Phase 2Q4 2031PembrolizumabVulva CancerNCT07290894

Primary: Objective Tumor Response Rate (ORR) (every 12 weeks from enrollment until disease progression (up to 72 months))Enrollment:Target 80Sites: 1NA, TREATMENT

Phase 3Q3 20322 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated CarcinomaNCT06632912

Primary: Geometric mean titers (GMTs) of neutralizing antibodies against HPV types 6, 11, 16, and 18 among subjects who were seronegative at baseline (pre-vaccination) (1 month after completion of the vaccination series)Enrollment:1,800/1,800Sites: 3RANDOMIZED, PREVENTION

Recent News & Research

bioRxiv

Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response Phenotypes

# Summary for Investors Researchers demonstrated that patient-derived ovarian cancer organoids can predict individual chemotherapy response better than standard biomarkers, potentially enabling personalized treatment selection and reducing ineffective therapy exposure. This functional stratification approach could improve clinical trial design and patient outcomes in a disease where chemotherapy resistance significantly limits survival, though clinical validation and commercialization pathways remain undefined. For TOIIW, the relevance depends on whether the company integrates organoid-based testing into its oncology care delivery model or develops partnerships with organoid developers.

Jul 7, 2026

bioRxiv

RAS-PI3K signaling promotes myofibroblastic CAF identity and restrains an immunomodulatory stromal program

# Research Summary: RAS-PI3K Signaling in Cancer-Associated Fibroblasts This preprint demonstrates that RAS-PI3K pathway activation in cancer-associated fibroblasts (CAFs) drives a myofibroblastic phenotype while suppressing immunomodulatory stromal functions, suggesting that targeting this pathway could reprogram the tumor microenvironment to enhance immune infiltration and anti-tumor immunity. For Oncology Institute's clinical portfolio, this identifies a potential combination strategy—RAS-PI3K inhibitors paired with immunotherapy—that could broaden efficacy across solid tumors by converting immunosuppressive stroma into a permissive state. The findings validate CAF reprogramming as a therapeutic target but require validation in clinical models to assess feasibility and patient selection criteria before informing treatment strategy decisions.

Jul 7, 2026

bioRxiv

Autoantibodies Drive Fc Gamma Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade

# Investment Summary: Oncology Institute, Inc. (TOIIW) **Clinical/Commercial Relevance:** This research identifies a mechanistic driver of immune checkpoint inhibitor (ICI)-induced colitis—a dose-limiting toxicity affecting ~10-20% of patients on anti-PD-1/PD-L1 therapies—through autoantibody-mediated Fc gamma receptor activation. Understanding this pathway could enable development of targeted interventions to prevent or manage ICI-related gastrointestinal toxicity, potentially allowing higher treatment doses and improved patient tolerability for oncology clinics. For TOIIW, which operates cancer treatment centers relying on checkpoint inhibitor regimens, this discovery has implications for refining patient selection, treatment protocols, and managing therapy-related complications that directly impact patient outcomes and treatment economics.

Jun 7, 2026

bioRxiv

Nature-Inspired Nanoparticle Adiposomes Enable Targeted Delivery of Hydrophobic Drug for Anti-Cancer Treatment

# Investment Summary: Nature-Inspired Nanoparticle Adiposomes **I cannot provide a specific analysis of this article's implications for Oncology Institute, Inc. (TOIIW) because:** 1. **Article does not appear to exist** – The June 7, 2026 date is in the future, and I have no record of this bioRxiv publication in my training data (current through April 2024). 2. **No disclosed connection to TOIIW** – Without access to the actual paper, I cannot determine whether this nanoparticle delivery technology relates to TOIIW's pipeline, partnerships, or therapeutic approach. 3. **Risk of misinformation** – Fabricating implications could mislead investment decisions. **What I'd recommend instead:** - Verify the publication date and locate the actual preprint on bioRxiv - Check TOIIW

Jun 7, 2026

Oncology Institute, Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research